Table of Contents
Introduction
The Bangladesh Pharmaceutical Export market is emerging as a key player in the global healthcare supply chain, driven by strong manufacturing capabilities, regulatory compliance, and competitive pricing. As of 2025, the pharmaceutical export market is experiencing rapid growth, with projections aiming to surpass USD 450 million, up from USD 275 million in FY 2022–23.
This momentum is fueled by rising global demand for quality generic medicines, especially in low- and middle-income countries across Asia, Africa, Latin America, and beyond.
Bangladeshi pharmaceutical companies such as Square Pharmaceuticals, Beximco Pharma, Incepta Pharmaceuticals, Renata Ltd., and ACI Ltd. are at the forefront of this export boom, expanding their footprint in regulated markets like the USA, UK, EU, and Australia.
Government support, TRIPS waiver benefits (until 2033 for LDCs), and increased investment in R&D and high-value formulations have further strengthened Bangladesh’s position in the global pharmaceutical supply chain.
You know here the current status, leading exporters, key markets, regulatory advancements, challenges, and the future outlook of Bangladesh’s pharmaceutical export industry in 2025 and beyond.
Current Scenario of Bangladesh Pharmaceutical Export Market
In FY 2024–25, Bangladesh’s pharma exports topped US $213 million, up from about $205 million in FY 2023–24—an annual increase of around 4%.
This marks more than double export earnings over the past seven years, as shipments grew from roughly $100 million to $213 million while expanding into 166 export markets globally .
Exporting Countries:
Asia: Myanmar, Vietnam, Sri Lanka, Philippines
Africa: Kenya, Nigeria, Tanzania, Sudan
Latin America: Peru, Chile, Panama
Europe: UK, Germany, Romania (via special approvals)
USA: Limited generic exports under FDA approval (e.g., Beximco)
| Region | % of Total Exports |
| Asia (India, Myanmar, etc.) | 32% |
| Africa (Kenya, Nigeria, etc.) | 24% |
| CIS Countries (Uzbekistan, Kazakhstan, etc.) | 15% |
| Middle East (Iraq, Yemen, etc.) | 12% |
| Latin America & Caribbean | 8% |
| Europe (Germany, UK, etc.) | 6% |
| North America (USA, Canada) | 3% |
Top Exporting Companies
1. Square Pharmaceuticals Ltd.
Holds the largest market share in the domestic pharma sector (about 18.8%) and leads in exports among Bangladeshi companies.
Started exporting in 1987; currently ships to over 36 countries across Asia, Africa, Europe, Latin America, and Australia.
Plays a central role in Bangladesh’s pharma export growth, contributing to the industry’s projected expansion from US $175 M in FY 2022‑23 to possibly US $450 M by 2025 and beyond.
2. Incepta Pharmaceuticals Ltd.
Ranked second in market share (about 10.2%) behind Square.
Exports to 60 or more countries, offering a broad portfolio of dosage forms including tablets, injectables, biosimilars, and vaccines.
Pioneered vaccine exports and is increasingly active in biotech—recently exported semaglutide-based drugs to 12 countries amid global demand.
Awarded export trophies multiple times (FY 2013–14, FY 2014–15, FY 2015–16) by the Government of Bangladesh.
3. Beximco Pharmaceuticals Ltd.
Bangladesh’s first pharma company approved by USFDA, enabling exports to the USA, Europe, Canada, Australia, and other regulated markets.
Supplies generic versions of patented drugs like remdesivir (Bemsivir) and molnupiravir (Emorivir) to over 50 countries.
Recognized as Bangladesh’s largest pharma exporter within the BEXIMCO group, with presence in more than 50–55 countries.
Holds about 5–7% domestic market share, ranking among the top four or five pharma exporters.
The Daily Star
Exports to 47–50 countries, including newly entered markets such as Australia—having received TGA approval for contraceptive exports.
Achieved 34.5% year-on-year export growth in fiscal 2022‑23, raising its share of Bangladesh’s pharma exports from 7.45% to 10.78%.
5. ACI Ltd. (ACI Pharmaceuticals)
A diversified conglomerate; its pharma division is among several strong exporters, though specific export figures for pharmaceuticals are less frequently disclosed.
Cited in industry projections (with Square, Incepta, Beximco, Renata) as one of the key contributors to growth—from US $175 M in FY 2022‑23 to potential US $450 M by 2025 and US $1.5 B by 2030.
Performance of Bangladesh Pharmaceutical Export Market (2016–2025)
| Fiscal Year | Export Value (USD Million) | Growth Rate (%) | No. of Export Countries | Notable New Markets |
| 2016–17 | 89 | — | 129 | Myanmar, Nepal |
| 2017–18 | 103 | +15.7% | 135 | Kenya, Nigeria |
| 2018–19 | 130 | +26.2% | 140 | Philippines, Sudan |
| 2019–20 | 136 | +4.6% | 144 | Uzbekistan |
| 2020–21 | 169 | +24.3% | 150 | Australia, Ecuador |
| 2021–22 | 188 | +11.2% | 155 | Colombia, Yemen |
| 2022–23 | 205 | +9.0% | 160 | Kazakhstan, Iraq |
| 2023–24 | 213 | +3.9% | 166 | Kyrgyzstan, Belarus |
| 2024–25* | Estimated 225 | +5.6% | 170+ | CIS Expansion, Ghana |
*2024–25 is based on projection trends and preliminary data.
Related Articles:
Top 20 Pharmaceutical Companies in Bangladesh 2024
Top 50 Pharmaceutical Companies in Bangladesh 2025
Top 20 Best Selling Drugs Globally in 2025
Key Export Products
Generic tablets and capsules (antibiotics, antihypertensives, antidiabetics)
Oncology drugs
Insulin & injectables
IV fluids
Topical formulations (creams, ointments)
Herbal and nutraceuticals
Why Bangladesh is Gaining Momentum in Pharmaceutical Export Market
| Strengths | Description |
| Low-cost Manufacturing | Competitive pricing compared to India or China |
| TRIPS Waiver till 2033 | Bangladesh can manufacture patented drugs without license |
| Improved Regulatory Compliance | WHO GMP, USFDA, UK MHRA approvals for some facilities |
| Skilled Workforce | Thousands of pharmacy graduates every year |
| Government Support | Export incentives, pharma export zones, tax rebates |
Challenges in the Export Market
Complex registration procedures in many countries
Limited presence in highly regulated markets like the USA and EU
Need for stronger pharmacovigilance and bioequivalence centers
Infrastructure gaps in cold chain and logistics
Need for branding and international marketing capabilities
Future Opportunities
Contract Manufacturing for Global Brands
Bangladesh can act as a manufacturing hub for western companies.
Biosimilar and Biotech Exports
Focus on insulin, monoclonal antibodies, and complex injectables.
Halal Pharmaceutical Products
Huge demand in OIC countries like Malaysia, Indonesia, UAE.
eCommerce Pharmacy Exports
Regulatory opening in global direct-to-patient delivery via online.
Key Strategies to Strengthen Export
Invest in regulatory affairs and global dossier preparation
Build bioequivalence testing labs and R&D centers
Set up dedicated pharma export processing zones (PEPZ)
Participate in international pharma expos & B2B meets
Collaborate with foreign distributors for better penetration
Policy & Regulatory Advantages
Bangladesh currently benefits from the TRIPS patent waiver as a Least Developed Country (LDC), allowing local firms to produce off‑patented drugs without royalty fees—but this privilege is scheduled to end in 2026 upon LDC graduation.
However, policy makers are lobbying to extend the TRIPS waiver until 2033, and to additionally support API production, R&D grants, and export subsidies—e.g., 7% subsidy for pharma, 20% for API exports.
Related Articles:
Top 20 Pharmaceutical Companies in Bangladesh 2024
Top 50 Pharmaceutical Companies in Bangladesh 2025
Top 20 Best Selling Drugs Globally in 2025
Infrastructure & API Capacity Building
The 200‑acre API Industrial Park in Munshiganj has been approved and is being developed, with around 27 companies setting up API manufacturing plants and expected production starting by 2026.
Currently, Bangladesh imports 85–95% of APIs, costing US $1.3 billion annually, but domestic production is intended to drastically reduce import dependency, lower unit costs, and enable higher-margin export manufacturing.
Outlook to 2030 & Beyond
Export Projections
Under a strong-growth scenario (20%+ CAGR, similar to past growth), exports could reach US $1 billion by 2029, and $1.3 billion by 2030.
A moderate path (10–12% CAGR) would still deliver $400–500 million export receipts by 2030
Long‑term government and industry targets ambitiously aim for $5 billion in pharma exports by 2027, though currently that remains aspirational; previous statements estimated exports around $1 billion in early 2020s.
Strategic Opportunities
With enhanced R&D and regulatory approvals (USFDA, EU GMP, MHRA, etc.), Bangladesh is scaling up biosimilars, oncology injectables, and hormone therapies where margins and demand are higher.
EU‑approved and US‑FDA‑compliant facilities could position Bangladesh as a contract manufacturing hub for international pharma companies—especially relevant amid trade tensions, tariffs, and supply disruptions in India and China.
Articles project that U.S. pharma import delays and tariffs (e.g. 25% tariffs announced in 2025) could open $50–100 million of extra U.S. export opportunity by 2027 for agile competitors like Bangladesh.
In addition to CIS, Bangladesh is penetrating markets across Africa, Southeast Asia, Latin America, and Middle East, where regulation is less stiff than in the U.S. or EU—and growth demand is rising.
Challenges
Loss of TRIPS waiver in 2026 could force firms to negotiate patent licenses or halt production of patented generics, increasing costs and reducing margins unless exemptions are arranged .
Compliance with stringent international regulations (FDA, EMA) remains a barrier, due to long approval timelines, high investment, and quality control demands Infrastructure gaps—cold chain logistics, port efficiency, API supply reliability—could hinder scaling unless improvements (e.g. the new Matarbari port corridor) are realized
Strategic Recommendations
| Focus Area | Key Actions |
| API Self‑Sufficiency | Expedite API Park operationalization, incentivize API R&D, localize critical molecules to reduce import dependence. |
| Regulatory Compliance | Upgrade quality systems, train workforce, pursue US FDA, EU MHRA, Health Canada, and TGA Australia approvals widely. |
| R&D & Innovation | Develop biosimilars, oncology portfolio, advanced formulations; encourage joint ventures with global pharma. |
| Market Diversification | Deepen presence in CIS, Africa, Latin America, and Middle East; pursue contract manufacturing alliances. |
| Policy Advocacy | Negotiate TRIPS waiver extension, maintain export incentives, streamline foreign investment & approvals, invest in logistics infrastructure. |
Conclusion
Bangladesh pharmaceutical export market ecosystem in 2025 is growing, diversified, and increasingly sophisticated. With exports exceeding US $213 million, the country is well on its path toward breaking out of low‑value generics into high‑value pharmaceuticals, biosimilars, and contract manufacturing.
The coming years—especially post-2026 LDC graduation—will test the resilience of the industry. Success hinges on scaling APIs, enhancing regulatory compliance, fostering innovation, and negotiating favorable policy frameworks.
If managed with strategic foresight, Bangladesh has the potential not just to reach US $1 billion exports by 2030, but ultimately to become a competitive global pharmaceutical hub—leveraging its cost advantage, expanding domestic infrastructure, and growing export networks across the world.
FAQ’s- Frequently Asked Questions
Who is the largest exporter of medicine?
Globally, the largest exporter of pharmaceuticals isGermany, followed by Switzerland, USA, Belgium, andIreland. These countries dominate due to innovation, biologics production, and FDA/EU GMP compliance.
What Is the Global Ranking of Bangladesh in medicine Exports?
Bangladesh ranks 71st among 134 countries in medicine exports, according to the Bangladesh Business Summit. While the country boasts a large and rapidly growing domestic pharmaceutical industry, it has also made notable progress in the global market. Bangladesh exports a wide range of pharmaceutical products to over 160 countries, with a strong emphasis on generic drugs, antibiotics, and cardiovascular medications. The industry continues to expand its footprint through competitive pricing, quality manufacturing, and regulatory compliance with international standards.
What is the Pharma industry outlook for 2025?
In 2025, Bangladesh’s pharmaceutical industry is expected to exceed USD 225 million in exports, with continued expansion into emerging markets like CIS, Africa, and Latin America. Domestically, the sector is projected to grow at 10–15% CAGR, driven by rising demand, strong generics manufacturing, and government support.
What is the future of the pharmaceutical industry in Bangladesh?
The future is highly promising. By 2030, Bangladesh aims to become a global hub for affordable generics, biosimilars, and contract manufacturing. With TRIPS waiver benefits (until 2026), API industrialization, and investment in FDA/EU-GMP-compliant facilities, the industry is poised to cross USD 1 billion in exports by 2029–30.
What is the future outlook for pharmaceutical sales?
Global pharmaceutical sales are expected to grow at 4–6% annually. Bangladesh’s domestic pharma market is growing even faster—12–14% CAGR—due to increased healthcare access, NCD prevalence, and insurance coverage. Export sales will likely see double-digit growth, especially in regulated and semi-regulated markets.
What is the pharmaceutical industry outlook for 2030?
By 2030:
Pharma exports may exceed USD 1.3 billion
API self-sufficiency may rise to 50–60%, reducing import burden
Bangladesh aims to be among the Top 25 pharma exporters globally
Advanced product portfolios including biologics, hormones, orphan drugs, and mRNA vaccines may enter the market
What is the ranking of medicine export in Bangladesh?
As of 2025:
Pharma ranks among Top 5 non-RMG export sectors in Bangladesh
Within SAARC, Bangladesh is 2nd after India in medicine export volume
Globally, Bangladesh ranks 71st medicine exporters, with ambitions to rise to Top 50 by 2030
Abdus Sobhan Salim is professional experienced pharmacist in pharmaceuticals, author and founder of pharmabossbd.com, the Bangladeshi pharmaceutical blogger since 2019.
